Back to News
Market Impact: 0.2
Supernus Pharmaceuticals Announces FDA Recognition of Seven Years of Orphan-Drug Exclusivity for ONAPGO
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Supernus Pharmaceuticals announced that the FDA recognized seven years of orphan-drug exclusive status, but the provided article excerpt ends before identifying the product or completing the announcement. The available information is insufficient to assess the commercial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
SUPN0.60
More News
- Huron Consulting stock rises on S&P SmallCap 600 addition
- SK Hynix shares slide after chipmaker scraps Solidigm IPO plans
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Musk's clash with Ukraine accelerates demand for Starlink alternatives. Few exist
- Trump invokes Cold War era Defense Production Act for oil production, refining